Introduction
Gastroparesis (GP) is characterized by chronic upper gastrointestinal (GI) symptoms in the presence of delayed gastric emptying without evidence of mechanical obstruction. GP is associated with substantial impairment in quality of life (QoL), which declines with increasing symptom severity and impacts daily activities and socioeconomic outcomes. Naronapride is a locally acting prokinetic agent with dual 5 HT4 receptor agonist and dopamine D2 receptor antagonist properties, exerting activity throughout the GI tract. This phase 2b trial assessed the efficacy and safety of naronapride administered for 12 weeks in adult patients with idiopathic or diabetic gastroparesis.
Aims & Methods
This international, multicenter, double-blind, randomized, placebo-controlled, phase 2b dose-finding trial enrolled adults with idiopathic or diabetic gastroparesis with confirmed delayed gastric emptying of solids at screening (NCT05621811). Participants received oral naronapride 10, 20, or 40 mg or placebo three times daily (TID) for 12 weeks. The primary endpoint was the change from baseline to week 12 in the average weekly American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) Core Symptom Score (a 5-point scale (0 = none, 4 = very severe) measuring nausea, vomiting, early satiety, postprandial fullness and upper abdominal pain. QoL was assessed using the validated, disease‑specific Patient Assessment of Upper Gastrointestinal Disorders–Quality of Life (PAGI‑QoL) score capturing treatment‑relevant impacts on daily activities, diet, psychological well‑being, clothing and relationships in a 6-point scale (0 = none of the time, 5 = all of the time).
Results
A total of 328 patients were randomized and treated (mean±SD age 51.1±14.7 years; 79.9% female; 27.4% diabetic etiology). Naronapride was superior to placebo on the primary endpoint at week 12 at a dose of 20 mg TID (difference to placebo: -0.405, p=0.005) and 40 mg TID (-0.346; p=0.016), but not 10 mg TID (-0.138; p= 0.311). Improvement in gastroparesis-related symptoms by naronapride also resulted in improved health‑related QoL as assessed by the PAGI‑QoL: naronapride was superior to placebo in improvements of the PAGI-QoL total score at week 12 at a dose of 20 mg TID (difference to placebo: -0.382, p=0.017) and 40 mg TID (-0.520; p=0.001), but not 10 mg TID (-0.295; p=0.070).
Naronapride was generally well-tolerated. Most adverse events (AEs) were dose-dependent and mainly GI motility–related, with mild or moderate diarrhea being the most common. Discontinuation rates due to AEs (most frequently GI-related) were higher with naronapride than placebo (9.9% vs. 2.4%). There was no cardiac or prolactin-related signal versus placebo, and glycemic control remained stable in diabetic patients.
Conclusion
In this phase 2b trial, naronapride significantly improved the cardinal symptoms of gastroparesis at 20 mg and 40 mg TID, which also resulted in significant improvements in disease specific quality of life. Naronapride was generally well tolerated, with mainly dose-dependent GI adverse events but no cardiac or prolactin-related safety concerns.
Disclosure
JT has given scientific advice to AlfaSigma, Enterra, Falk, Promed, Truvion, Tsumura Pharmaceuticals, received research support from Biohit and ProMed and served on the Speaker bureau for Abbott, ProMed, Schwabe, Thai Meiji and Truvion Pharmaceuticals. FW, TN, and RM are employees of Dr. Falk Pharma. All remaining authors disclose no conflicts of interest.